Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacity

Aragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-molecule CDMO capacity and a biologics facility. Aragen aims to transition from a molecules company to a medicines company through expansion. This strategic move aligns with global drugmakers seeking supply chain alternatives outside China. The firm is also developing its own intellectual property around antibody-drug conjugates.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LxkSpVN
via IFTTT

Read More

Karnataka medical institute opened by PM plans free cancer immunotherapy for patients

The Sri Madhusudan Sai Institute plans to offer free immunotherapy for cancer patients. A new 600-bed hospital will soon launch on campus, expanding free medical services. Modern genomics treatment is already initiated, and rare disease research is underway. The mission has invested significantly in service initiatives and seeks corporate and international support. Free paediatric healthcare and nutrition programs are also highlighted as key achievements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jH0WehJ
via IFTTT

Read More

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger scientific evidence and safety monitoring for wider adoption. The Central Council for Research in Ayurvedic Sciences stressed this at a symposium. Discussions focused on safety and evidence-based care for non-communicable diseases. The council highlighted its work in public health and traditional medicine. Strengthening pharmacovigilance is crucial for patient safety in Ayurveda.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BYGD7aX
via IFTTT

Read More

ENTOD Pharmaceuticals secures patent for its insulin eye drop

Currently at the pre-clinical stage of development, the patented insulin eye drops are being investigated as a potential novel therapeutic approach to address unmet needs in ophthalmic care, the Mumbai-based company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IVdDPMv
via IFTTT

Read More

When doctor is at home: Technology enables 24x7 monitoring beyond hospital

A new technology offers continuous remote health monitoring for patients at home. This system helps individuals recovering from surgery and the elderly stay supervised. Patients receive regular check-ins and immediate advice for any health abnormalities. The technology uses biosensors to track vital signs and prevent emergencies. This innovation provides reassurance and timely medical support for many individuals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PyEDvtO
via IFTTT

Read More

Drugs Panel to weigh bringing all sterile drug products under central licensing amid contamination concerns

A proposal will soon be considered to centralize licensing for all sterile drug products. This move aims to tighten regulations on medicines prone to microbial contamination. Currently, only specific sterile medicines fall under central licensing authority. The proposal highlights fragmented existing frameworks and varying state inspection practices. Bringing all sterile products under central oversight will create a uniform regulatory system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUrDiCs
via IFTTT

Read More

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGtOv2Z
via IFTTT

Read More